‘Pulmonary Arterial Hypertension (PAH)- Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PAH’s in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted market size of Pulmonary Arterial Hypertension (PAH) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered • The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2017–2030
Pulmonary Arterial Hypertension (PAH) - Disease Understanding and Treatment Algorithm
Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension which is characterized by the elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from the right side of the heart through lungs. It occurs due to the tightening and stiffening of the small pulmonary arteries leading to the right ventricular dysfunction and vessel obstruction.
The Pulmonary Arterial Hypertension (PAH) market report gives the thorough understanding of the PAH by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Pulmonary Arterial Hypertension in the US, Europe and Japan.
Pulmonary Arterial Hypertension Epidemiology The Pulmonary Arterial Hypertension (PAH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of PAH, subtype-specific population of PAH and gender-specific PAH diagnosed pool) scenario of Pulmonary Arterial Hypertension (PAH) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.
According to the report, the total number of prevalent cases of Pulmonary Arterial Hypertension (PAH) in 7MM was found to be 70,774, in the year 2017.
Pulmonary Arterial Hypertension Drug Chapters This segment of the Pulmonary Arterial Hypertension report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The therapeutic market of Pulmonary Arterial Hypertension is driven by the use of endothelin receptor antagonists, prostanoids, and phosphodiesterase inhibitors for the treatment of Pulmonary Arterial Hypertension. Among these therapeutics endothelin receptor antagonists are most widely used for the treatment of PAH. Letairis\Volibris (GlaxoSmithKline plc\Gilead Science), Opsumit (Actelion Pharmaceuticals Ltd), and Tracleer (Actelion Pharmaceuticals Ltd) are mostly recommended endothelin receptor antagonists being used for the treatment of Pulmonary Arterial Hypertension. These antagonists act by relaxing blood vessels and inhibiting proliferation and remodeling of blood vessels.
Pulmonary Arterial Hypertension Market Outlook The Pulmonary Arterial Hypertension market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the report, the market of Pulmonary Arterial Hypertension in 7MM was found to be USD 4.6 Billion in 2017, and is expected to increase during the course of the study period (2017–2030). Among the 7MM, the United States accounts for the largest market size of PAH, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Pulmonary Arterial Hypertension Drugs Uptake This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017–2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Pulmonary Arterial Hypertension Report Insights • Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Key Benefits • This report will help to develop Business Strategies by understanding the trends shaping and driving Pulmonary Arterial Hypertension market
• Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension market
• To understand the future market competition in the Pulmonary Arterial Hypertension market.
Our reports have been used by over 10K customers, including:
175 pages •
By The Business Research Company
• Apr 2021
Major players in the polymerase chain reaction (PCR) and real-time polymerase chain reaction (PCR) testing market are Abbott Laboratories, Agilent Technologies Inc., Biomerieux Sa, Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd (Roche Diagnostics), Qiagen N.V., Genmark Diagnostics, Thermo Fisher Scientific Inc., General Electric Company (Ge...
200 pages •
By The Business Research Company
• Dec 2020
Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline (GSK), Novartis AG and Novo Nordisk A/S. The global biosimilar therapeutic peptides market is expected to decline from $0.80 billion in 2019 to $0.77...
The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages,...
KEY FINDINGS The Europe apheresis market is forecasted to develop with a CAGR of 8.20% during the estimated period of 2021 to 2028. The region’s market growth is stimulated by factors such as the increasing blood donation across nations, the rising numbers of apheresis procedures to treat therapeutic conditions, the growing...
200 pages •
By The Business Research Company
• Dec 2020
Major players in the erythropoietin (EPO) market are Amgen Inc., Johnson & Johnson, Roche Group, Pfizer Inc., Novartis, Celltrion Inc and LG Life Sciences Ltd. The global erythropoietin (EPO) market is expected to decline from $1.01 billion in 2019 to $0.95 billion in 2020 at a compound annual growth rate (CAGR) of -6.27%. The decline...
The Europe electronic skin patches market is registered to project a CAGR of 16.41%, during the forecast years of 2021 to 2028. The region’s key market growth drivers are, the surging number of research and development activities, the rising healthcare expenditure, and the increasing geriatric population.
The Europe 3D Ultrasound Market would witness market growth of 8% CAGR during the forecast period (2020-2026). The driving elements for the development of the ultrasound devices market incorporate the government and private subsidizing for R&D in ultrasound imaging, an expanding number of medical care suppliers, development in technology,...
The Europe Urinary Drainage Bags Market would witness market growth of 5.4% CAGR during the forecast period (2020-2026). The swift increase in the geriatric population is the main factor that is responsible for the growing demand for urinary drainage bags. Numerous changes occur in the urinary system of an old person such as weakening...
‘Chronic kidney disease (CKD)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Chronic kidney disease in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
Chronic Kidney Disease (CKD) Understanding
Summary Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics based on hypoxia inducible factor for patients with kidney disease and other metabolic disorders.Its lead product candidate vadadustat is a HIF-PH inhibitor, a regulator...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.